Literature DB >> 851058

Acute hemodynamic effects of an alpha- and beta-receptor blocking agent (AH 5158) on the systemic and pulmonary circulation at rest and during exercise in hypertensive patients.

G Koch.   

Abstract

The acute hemodynamic effects of 50 mg. of the alpha- and beta-receptor blocking agent AH 5158, administered intravenously, on the systemic and pulmonary circulation were studied in 13 hypertensive patients at rest in the supine and erect positions, and during exercise, with right heart and brachial artery catheterization. AH 5158 induced a significant fall of systemic blooc pressures under all conditions, whereas the pulmonary systolic and mean pressures were lower at rest and unaltered during exercise. The left ventricular filling pressure largely remained unchanged. Blood pressure was lowered predominantly by a reduction in systemic vascular resistance together with a reduction in cardiac output. These effects were particularly pronounced in the erect position and during exercise. Cardiac output was lowered solely by the reduction of heart rate; stroke volume was unchanged or even increased. The arterial-mixed venous oxygen difference increased in the erect position and during exercise. The pattern of AH 5158-induced hemodynamic adaptation comprising a reduction of both vascular resistance and cardiac output, without evidence of significant negative inotropic action, offers a novel basis for treating hypertension with a single drug. Its pharmacological and hemodynamic profile suggests considerable potential in the treatment of hypertensive patients.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 851058     DOI: 10.1016/s0002-8703(77)80008-2

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  10 in total

1.  Haemodynamic adaptation at rest and during exercise to long-term antihypertensive treatment with combined alpha- and beta-adrenoreceptor blockade by labetalol.

Authors:  G Koch
Journal:  Br Heart J       Date:  1979-02

Review 2.  Labetalol: a review of its pharmacology and therapeutic use in hypertension.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1978-04       Impact factor: 9.546

3.  The influence of labetalol on arterial blood gas data, pulmonary haemodynamics and pulmonary shunting.

Authors:  S G De Hert; L G Heytens; R G De Jongh; M P Vercauteren; E A Boeckx; H F Adriaensen
Journal:  Intensive Care Med       Date:  1988       Impact factor: 17.440

4.  Cardiovascular dynamics after acute and long-term alpha- and beta-adrenoceptor blockade at rest, supine and standing, and during exercise.

Authors:  G Koch
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

Review 5.  Clinical pharmacology of labetalol.

Authors:  D A Richards; B N Prichard
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

6.  Acute and long-term effects of labetalol on systemic and pulmonary haemodynamics in hypertensive patients.

Authors:  T L Svendsen; S Rasmussen; O J Hartling; P E Nielsen; J Trap-Jensen
Journal:  Eur J Clin Pharmacol       Date:  1980-01       Impact factor: 2.953

7.  Response of the systemic pulmonary circulation to labetalol at rest and during exercise.

Authors:  R Fagard; P Lijnen; A Amery
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

8.  Transfer of labetalol into amniotic fluid and breast milk in lactating women.

Authors:  N O Lunell; J Kulas; A Rane
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

9.  Effects of combined alpha- and beta-blockade by labetalol in patients with coronary artery disease.

Authors:  M Condorelli; G Brevetti; M Chiariello; D Miceli; G Lavecchia; G Paudice; S Verrienti
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

Review 10.  Pharmacology of combined alpha-beta-blockade. I.

Authors:  W J Louis; J J McNeil; O H Drummer
Journal:  Drugs       Date:  1984       Impact factor: 9.546

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.